Scanfil Oyj
14.1.2021 13:02:43 CET | Globenewswire | Press release
SCANFIL PLC MANAGERS' TRANSACTIONS 14 January 2021 2 P.M.
Scanfil plc: Managers' transactions
Person subject to the notification requirement
Name:
Jokitalo Juha Petteri
Position:
Chief Executive Officer
Issuer:
Scanfil Oyj
LEI:
7437004XD6U0FFDCT507
Notification type:
INITIAL NOTIFICATION
Reference number:
7437004XD6U0FFDCT507_20210114123555_2
____________________________________________
Transaction date:
2021-01-11
Venue:
NASDAQ HELSINKI LTD (XHEL)
Instrument type:
SHARE
ISIN:
FI4000029905
Nature of the transaction:
DISPOSAL
Transaction details
(1): Volume: 110,000 Unit price: 6.5 EUR
Aggregated transactions
(1): Volume: 110,000 Volume weighted average price: 6.5 EUR
SCANFIL PLC
Petteri Jokitalo
CEO
For additional information:
CEO Petteri Jokitalo
tel. +358 8 4882 111
www.scanfil.com
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
trivago N.V.3.2.2026 22:40:00 CET | Press release
trivago N.V. reports solid Q4 2025 results, achieving 27% YoY revenue growth
Copper Mountain Technologies3.2.2026 21:24:50 CET | Press release
Copper Mountain Technologies Advances Global Production Strategy with Expanded Manufacturing Operations in Cyprus
UNICOM Engineering, Inc.3.2.2026 20:45:30 CET | Press release
Asperitas and UNICOM Engineering Deliver a Single-Contract Path to Immersion-Cooled Compute Infrastructure
Verisk Analytics, Inc.3.2.2026 20:22:54 CET | Press release
Verisk Estimates Insured Losses for Winter Storm Fern Could Reach USD 4 Billion
Neomorph, Inc.3.2.2026 19:08:00 CET | Press release
Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom